ALNYLAM PHARMACEUTICALS, INC. cotiza a 223.82 USD y tiene una capitalización bursátil de $29.9B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvi…
| Periodo | 2026-10 | 2026-07 | 2026-04 | 2026-02 |
|---|---|---|---|---|
| Real | — | $1.84 | $1.99 | $1.25 |
| Estimado | $2.30 | $2.14 | $1.47 | $1.50 |
| Sorpresa | — | -14.0% | +35.4% | -16.7% |
| Métrica | ALNY | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 81.8% | 57.0% | +24.7% |
| Operating Margin | 13.5% | -38.6% | +52.1% |
| Net Margin | 8.4% | -33.6% | +42.0% |
| FCF Margin | 12.5% | -13.9% | +26.4% |
| ROE | 39.8% | -40.4% | +80.2% |
| ROA | 6.3% | -32.0% | +38.3% |
| Current Ratio | 2.76 | 2.84 | -0.08 |
| Debt / Equity | — | 0.28 | — |